Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BHST vs ZSPC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BHST Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–2 Matrix Metrics)
BHST Overall Winner
6-Pillar Tally: BHST 5 – 0 ZSPC (1 Tie)
Matrix Metrics: BHST 6 – 2 ZSPC
As of Nov 20, 2026, BioHarvest Sciences Inc. (BHST) is the stronger overall head-to-head candidate over zSpace, Inc. (ZSPC) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BHST carries a Unified Composite Score of 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin), whereas ZSPC carries 59.8/100 (HOLD) at $0.24 (N/M Forward P/E, -116.2% operating margin).
- Composite vs. Pillar Nuance: While ZSPC currently prints a higher short-term Unified Composite Score (59.8/100 HOLD vs. BHST 58.2/100 HOLD), BHST captures the overall institutional head-to-head verdict (6–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-18.0% vs. -116.2% operating margin) and revenue trajectory (+3.8% vs. -43.2% YoY).
- Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile ZSPC is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BHST vs ZSPC
BHST
Head-to-Head Winner
BioHarvest Sciences Inc. Common Stock
$1.30
-1.52% 1D
Market Cap
$29.9M
TTM Revenue
$35M
Forward P/E
N/M
Beta / 30D Vol
0.25β · 86% Vol
Unified Composite Score
58.2
HOLD
Tech 75.0
Fund 57.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
ZSPC
zSpace, Inc. Common stock
$0.24
-45.79% 1D
Market Cap
$1.3M
TTM Revenue
$28M
Forward P/E
N/M
Beta / 30D Vol
-10.63β · 6994% Vol
Unified Composite Score
59.8
HOLD
Tech 60.0
Fund 57.0
Flow 50.0
Mom 58.5
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (BHST 5 – 0 ZSPC)
1. Valuation Multiples
BHST
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.7x
N/M
2. Growth & Scale
BHST
Revenue Growth (YoY)
+3.8%
-43.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$35M
$28M
Market Cap
$29.9M
$1.3M
3. Profitability & Quality
BHST
Gross Margin
59.0%
47.6%
Operating Margin
-18.0%
-116.2%
Net Profit Margin
-31.2%
-91.1%
Return on Equity (ROE)
-142.5%
0.0%
4. Balance Sheet & Cash Flow
BHST
Cash Generation (TTM)
-$9.4M
-$22M EBITDA
Cash Flow Margin
-26.6%
-79.4% EBITDA Mgn
Net Cash / Leverage
$5.1M Net Cash
0.0% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Distribution
6. R&D & Supply-Chain Moat
BHST
OpEx & R&D Intensity
77.0% of Rev ($27M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Packaged Foods Operator
Computer Hardware Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BHST (6) vs ZSPC (2)| Institutional Metric | BHST | ZSPC | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $29.9M | $1.3M | BHST | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +3.8% | -43.2% | BHST | |
| Operating Margin (TTM) | -18.0% | -116.2% | BHST | |
| Net Profit Margin | -31.2% | -91.1% | BHST | |
| Return on Equity (ROE) | -142.5% | 0.0% | ZSPC | |
| 52-Week Range Position | 6% ($1–$7) | 2% ($0–$10) | BHST | |
| Beta / 30D Volatility | 0.25β · 86% Vol | -10.63β · 6994% Vol | BHST | |
| Unified Institutional Score | 58.2 / 100 (HOLD) | 59.8 / 100 (HOLD) | ZSPC | |
| Trailing 12M Revenue (USD) | $35M | $28M | Scale | |
| Gross Profit Margin (TTM) | 59.0% | 47.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.7x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$9.4M ($5.1M Net Cash) | -$22M EBITDA (0.0% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ZSPC +69.68 pp
3M Horizon
BHST +38.35 pp
6M Horizon
BHST +30.61 pp
1Y Horizon
BHST +30.61 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BHST Revenue | ZSPC Revenue | BHST Op. Margin | ZSPC Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2023 | $10M | N/A | -78.6% | N/A | BHST |
| FY2024 | $30M | $40M | -27.7% | -46.3% | BHST |
| FY2025 | $30M | $30M | -16.2% | -79.5% | BHST |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BHST
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ZSPC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ZSPC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BHST Moat Profile
Cyclical / Execution-Driven Positioning
Packaged Foods Operator
OpEx & R&D Reinvestment
77.0% of Rev ($27M)
90D Engineering Disclosures
0 Published
ZSPC Moat Profile
Cyclical / Execution-Driven Positioning
Computer Hardware Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ BHST vs ZSPC Key Questions & Quantitative Answers
As of Nov 20, 2026, BioHarvest Sciences Inc. (BHST) is the stronger overall head-to-head candidate over zSpace, Inc. (ZSPC) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BHST carries a Unified Composite Score of 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin), whereas ZSPC carries 59.8/100 (HOLD) at $0.24 (N/M Forward P/E, -116.2% operating margin). Composite vs. Pillar Nuance: While ZSPC currently prints a higher short-term Unified Composite Score (59.8/100 HOLD vs. BHST 58.2/100 HOLD), BHST captures the overall institutional head-to-head verdict (6–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-18.0% vs. -116.2% operating margin) and revenue trajectory (+3.8% vs. -43.2% YoY). Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile ZSPC is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BHST leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with ZSPC at -43.2% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (47.6% gross margin, -116.2% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), BHST cumulative revenue shifted +200.0% while ZSPC shifted -25.0%. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZSPC.
BHST screens cheaper on headline valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas ZSPC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-79.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus ZSPC (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, ZSPC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-10.63β · 6994% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ZSPC vs BHST · Reverse Pair
BHST vs ACOG
· Sector Peer
BHST vs ELVA
· Sector Peer
BHST vs KGEI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking